Celcuity hits record high on breast cancer drug trial data

Celcuity

28/07/2025 15:37

Updates

** Shares of drug developer Celcuity CELC.O surge 197% to all-time high of $40.93

** Stock set for its best day on record, if gains hold

** Co says its experimental drug, gedatolisib, combined with Pfizer's PFE.N Ibrance and AstraZeneca's AZN.L Faslodex, delayed advanced breast cancer progression by more than seven months, compared to Faslodex alone in a late-stage study

** The triple combo drug cut the risk of disease progression or death by 76%, compared to Faslodex in previously treated HR+/HER2- advanced breast cancer patients, co says

** The study showed "unprecedented results", Leerink Partners analyst Andrew Berens says, adding that gedatolisib could become a new standard of care as a second-line treatment in breast cancer, especially in the community settings

** Triple combo patients lived 9.3 months without progression versus two months with Faslodex alone, co adds

** CELC says the treatment was better tolerated than in previous early-stage studies, with lower rates of high blood sugar and mouth inflammation

** CELC says it plans to apply for U.S. marketing approval in Q4 2025

** As of last close, stock up 5.2% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))